Fulcrum Therapeutics (NASDAQ:FULC) VP Peter G. Thomson sold 5,000 shares of the stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $17.22, for a total value of $86,100.00. Following the sale, the vice president now directly owns 33,833 shares in the company, valued at $582,604.26. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
FULC opened at $18.13 on Tuesday. Fulcrum Therapeutics has a 52-week low of $4.37 and a 52-week high of $22.96. The stock’s fifty day moving average is $16.37.
Fulcrum Therapeutics (NASDAQ:FULC) last released its earnings results on Thursday, November 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.35). Research analysts anticipate that Fulcrum Therapeutics will post -4.03 earnings per share for the current year.
Several hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System bought a new stake in shares of Fulcrum Therapeutics during the 3rd quarter worth $47,000. Millennium Management LLC bought a new stake in shares of Fulcrum Therapeutics during the 3rd quarter worth $2,065,000. TRV GP IV LLC bought a new stake in shares of Fulcrum Therapeutics during the 3rd quarter worth $15,559,000. Finally, TRV GP Iii LLC bought a new stake in shares of Fulcrum Therapeutics during the 3rd quarter worth $39,589,000. Institutional investors and hedge funds own 65.09% of the company’s stock.
Several analysts have recently issued reports on the company. Zacks Investment Research raised Fulcrum Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 21st. ValuEngine lowered Fulcrum Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. Finally, HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of Fulcrum Therapeutics in a report on Tuesday, December 24th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Fulcrum Therapeutics currently has a consensus rating of “Buy” and an average target price of $23.00.
About Fulcrum Therapeutics
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia.
Featured Story: Monthly Dividend Stocks
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.